Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CELZ-201 in recent onset type 1 diabetes
NCT05626712Phase 2Recruiting
- Sponsor
- Creative Medical Technology Holdings, Inc.
- Start
- Apr 2023
- Primary completion
- Jan 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CELZ-201 in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Creative Medical Technology Holdings, Inc. Primary endpoint: Number of Participants with Adverse Events at 6 months. Started Apr 2023; status: recruiting.
02
Drugs
CELZ-201
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05626712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05626712.